Currently out of the existing stock ratings of Luca Issi, 69 are a HOLD (41.32%), 97 are a BUY (58.08%), 1 are a SELL (0.6%).

Luca Issi

Work Performance Price Targets & Ratings Chart

Analyst Luca Issi, currently employed at RBC, carries an average stock price target met ratio of 37.2% that have a potential upside of 57.91% achieved within 120 days.

Luca Issi’s has documented 332 price targets and ratings displayed on 23 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on EDIT, Editas Medicine at 13-Dec-2024.

Wall Street Analyst Luca Issi

Analyst best performing recommendations are on BLUE (BLUEBIRD BIO).
The best stock recommendation documented was for BLUE (BLUEBIRD BIO) at 11/15/2024. The price target of $4 was fulfilled within 28 days with a profit of $3.68 (1150%) receiving and performance score of 410.71.

Average potential price target upside

of $53.9 (28.76%) on ALNY (ALNYLAM PHARMACEUTICALS).
of $24.7 (26.82%) on MRNA (MODERNA).
of $22.84 (52.49%) on ARWR (ARROWHEAD PHARMACEUTICALS).

ALLO Allogene Therapeutics ALNY Alnylam Pharmaceuticals ARWR Arrowhead Pharmaceuticals BLUE Bluebird bio CRSP Crispr Therapeutics AG DRNA Dicerna Pharmaceuticals IONS Ionis Pharmaceuticals RGNX Regenxbio WVE Wave Life Sciences Ltd SGMO Sangamo Therapeutics ADVM Adverum Biotechnologies CRBU Caribou Biosciences EDIT Editas Medicine FIXX Homology Medicines NTLA Intellia Therapeutics GRPH Graphite Bio VERV Verve Therapeutics MRNA Moderna MGTX MeiraGTx Holdings PLC BEAM Beam Therapeutics BMRN Biomarin Pharmaceutical QURE Uniqure NV FDMT 4D Molecular Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Robert Burns (HC WAINWRIGHT)